OPFOLDA – Cost

OPFOLDA, HCPCS J1202, became effective on April 1, 2024, and has three NDCs mapped to J Code: J1202. There has been no change in pricing since inception. AWP has remained slightly higher than WAC.

RYKINDO – Cost

RYKINDO, became effective on April 1, 2024, and is associated with HCPCS J2801. RYKINDO has six NDCs mapped to J Code: 2801 with no discrepancies found within these alignments. Pricing between WAC and AWP have remained relatively close with no substantial movement.

Veopoz – Cost

Veopoz, manufactured by REGENERON PHARMACEUTICALS, became effective on April 1, 2024 and is associated with HCPCS J9376. Veopoz has two NDCs aligned to J Code: J9376. Since inception, pricing has remained level with AWP being 20% higher than WAC.

CEFAZOLIN – Cost

CEFAZOLIN’s HCPCS J0688, became effective on January 1, 2024. CEFAZOLIN has two NDCs aligned to J Code: J0688 with no errors found. ASP has held just over 30% below WAC.

REZZAYO – Cost

REZZAYO, a product of MELINTA THERAPEUTICS, LLC, became effective on October 1, 2023 and is aligned to J Code: J0349. From the end of 2023 through the first quarter of 2024, prices have remained steadt.

SINCALIDE – Cost

SINCALIDE, became effective on July 1, 2023, and is associated with HCPCS J2806. There are two NDCs aligned to J Code: J2806 with one possible error found within these mappings. Prices have remained level through the beginning of 2024.

BYFAVO – Cost

BYFAVO’s HCPCS became effective on July 1, 2023. There are two NDCs aligned to J Code: J2249 with one possible error or discrepancy found. AWP and WAC have remained level at their introductory prices through the first quarter of 2024.

FUROSCIX – Cost

FUROSCIX, manufactured by SCPHARMACEUTICALS, became effective on July 1, 2023, and is aligned to J Code: J1941. Through the end of 2023, both WAC and AWP remained unchanged. At the beginning of 2024, both experienced a slight increase of roughly 10%.